[go: up one dir, main page]

ATE249244T1 - Aktivierte verbindungen und verfahren zur herstellung und reiningung - Google Patents

Aktivierte verbindungen und verfahren zur herstellung und reiningung

Info

Publication number
ATE249244T1
ATE249244T1 AT96944251T AT96944251T ATE249244T1 AT E249244 T1 ATE249244 T1 AT E249244T1 AT 96944251 T AT96944251 T AT 96944251T AT 96944251 T AT96944251 T AT 96944251T AT E249244 T1 ATE249244 T1 AT E249244T1
Authority
AT
Austria
Prior art keywords
pegs
production
purification
methods
activated compounds
Prior art date
Application number
AT96944251T
Other languages
English (en)
Inventor
Prabha N Ibrahim
Robert A Baile
James Ervin Seely
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE249244T1 publication Critical patent/ATE249244T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Road Signs Or Road Markings (AREA)
  • Thermistors And Varistors (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96944251T 1996-03-06 1996-12-06 Aktivierte verbindungen und verfahren zur herstellung und reiningung ATE249244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/611,918 US5747639A (en) 1996-03-06 1996-03-06 Use of hydrophobic interaction chromatography to purify polyethylene glycols
PCT/US1996/019459 WO1997032607A2 (en) 1996-03-06 1996-12-06 Activated linkers and methods for making and purifying the same

Publications (1)

Publication Number Publication Date
ATE249244T1 true ATE249244T1 (de) 2003-09-15

Family

ID=24450930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96944251T ATE249244T1 (de) 1996-03-06 1996-12-06 Aktivierte verbindungen und verfahren zur herstellung und reiningung

Country Status (11)

Country Link
US (2) US5747639A (de)
EP (1) EP0906122B1 (de)
JP (1) JP2000506851A (de)
AT (1) ATE249244T1 (de)
AU (1) AU720399B2 (de)
CA (1) CA2248006C (de)
DE (1) DE69629949T2 (de)
DK (1) DK0906122T3 (de)
ES (1) ES2206616T3 (de)
PT (1) PT906122E (de)
WO (1) WO1997032607A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
DK0942740T3 (da) 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
AU725133B2 (en) * 1997-01-15 2000-10-05 Polaris Group Modified tumor necrosis factor
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
CZ299164B6 (cs) 1998-10-16 2008-05-07 Biogen Idec Ma Inc. Farmaceutická kompozice obsahující glykosylovaný interferon-beta-1a navázaný na polymer
SK287491B6 (sk) * 1998-10-16 2010-11-08 Biogen Idec Ma Inc. Fúzne proteíny interferónu- beta-1a a ich použitie
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
EP1250154B1 (de) 2000-01-10 2009-07-01 Maxygen Holdings Ltd G-csf konjugate
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
DK1411970T3 (da) * 2000-12-06 2007-06-04 Applied Research Systems Anvendelse af SARP-1 til behandling og/eller forebyggelse af sclerodermia
JP2004534523A (ja) 2001-02-27 2004-11-18 マキシゲン・エイピーエス 新規なインターフェロンβ様分子
JP2005508365A (ja) * 2001-10-29 2005-03-31 ネクター セラピューティックス エイエル,コーポレイション プロテインキナーゼcインヒビターのポリマー結合体
EP3025726B1 (de) 2002-01-18 2019-11-20 Biogen MA Inc. Polyalkylen-polymer-verbindungen und verwendungen davon
KR101186140B1 (ko) 2002-06-21 2012-09-27 노보 노르디스크 헬스 케어 악티엔게젤샤프트 페길화된 인자 vii 글리코형태
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
RS20050501A (en) * 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
CN1867581B (zh) 2003-10-10 2012-02-01 诺沃挪第克公司 Il-21衍生物
EP2633866A3 (de) 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
GB2426521A (en) 2004-02-02 2006-11-29 Ambrx Inc Modified human four helical bundle polypeptides and their uses
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
CA2569381A1 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
KR101252835B1 (ko) 2004-12-22 2013-04-10 암브룩스, 인코포레이티드 아미노아실-tRNA 합성효소의 조성물 및 그것의 용도
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
AU2005322019B2 (en) 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
KR20080026135A (ko) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
NZ565294A (en) 2005-08-18 2010-06-25 Ambrx Inc Compositions of tRNA and uses thereof
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
KR20090042755A (ko) 2006-02-28 2009-04-30 닥터 레디즈 레버러토리즈 (이유) 리미티드 폴리에틸렌 글리콜 카보네이트의 제조방법
WO2007135182A2 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Factor ix analogues having prolonged in vivo half life
AU2007292892B9 (en) 2006-09-08 2013-02-28 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
EP2615108B1 (de) 2006-09-08 2016-10-26 Ambrx, Inc. Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
ES2465473T3 (es) 2006-09-08 2014-06-05 Ambrx, Inc. Transcripción de arnt supresor en células de vertebrado
US8222039B2 (en) * 2007-02-22 2012-07-17 Biovectra Inc. Process for purification of water soluble polymers
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 fgf-21 폴리펩티드 및 그 용도
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
DK2217265T3 (en) 2007-11-20 2017-07-03 Ambrx Inc Modified insulin polypeptides and their use
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
WO2010011735A2 (en) 2008-07-23 2010-01-28 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
JP5694171B2 (ja) 2008-09-26 2015-04-01 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されている動物のエリスロポエチンポリペプチドおよびそれらの使用
JP2013515080A (ja) 2009-12-21 2013-05-02 アンブルックス,インコーポレイテッド 修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用
EA201290542A1 (ru) 2009-12-21 2013-07-30 Амбркс, Инк. Модифицированные свиные соматотропиновые полипептиды и их применение
EP3815708A1 (de) 2010-03-05 2021-05-05 Omeros Corporation Chimäre inhibitormoleküle mit komplementaktivierung
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
ES2972902T3 (es) 2010-08-17 2024-06-17 Ambrx Inc Polipéptidos de relaxina modificados y sus usos
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
EP3135690A1 (de) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
ES2907763T3 (es) 2012-08-31 2022-04-26 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
JP2016518311A (ja) * 2013-03-08 2016-06-23 ユニヴァーシティー オブ サザン カリフォルニア ビニルスルホン系18f標識化組成物ならびにその方法およびその使用
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9840493B2 (en) 2013-10-11 2017-12-12 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
TWI654440B (zh) 2013-11-15 2019-03-21 美商實體科學公司 具有親水層的隱形眼鏡
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
WO2016094533A1 (en) 2014-12-09 2016-06-16 Ocular Dynamics, Llc Medical device coating with a biocompatible layer
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
US12049485B2 (en) 2018-09-11 2024-07-30 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
EP4028159A1 (de) 2019-09-10 2022-07-20 Pierce Biotechnology, Inc. Probenvorbereitungszusammensetzungen, vorrichtungen, systeme und verfahren
CA3174114A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
JP2023538071A (ja) 2020-08-20 2023-09-06 アンブルックス,インコーポレイテッド 抗体-tlrアゴニストコンジュゲート、その方法及び使用
KR20240004342A (ko) 2021-04-03 2024-01-11 암브룩스, 인코포레이티드 항-her2 항체-약물 접합체 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004203A1 (en) * 1987-11-10 1989-05-18 North Carolina State University Chromatography apparatus and method and material for making the same
US5094960A (en) * 1988-10-07 1992-03-10 New York Blood Center, Inc. Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5645717A (en) * 1989-01-13 1997-07-08 Bio-Rad Laboratories, Inc. Hydrophobic polymers from water-soluble monomers and their use as chromatography media
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
SG89295A1 (en) * 1991-03-15 2002-06-18 Amgen Inc Pegylation of polypeptides
WO1993001498A1 (en) * 1991-07-04 1993-01-21 Immunodex K/S Water-soluble, polymer-based reagents and conjugates comprising moieties derived from divinyl sulfone
US5424063A (en) * 1992-01-09 1995-06-13 The Dow Chemical Company Narrow poly- and mono-dispersed anionic oligomers, and their uses, formulations and process
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
EP0622394A1 (de) * 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Umkehrbare Modifikation von Verbindungen, Schwefel enthaltend, mit Polyalkylengycol und ihre Verwendung
ATE171276T1 (de) * 1993-07-16 1998-10-15 Merck Patent Gmbh Trennmaterialien für die hydrophobe chromatographie
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5476643A (en) * 1993-11-19 1995-12-19 Bernel Chemical Co. Method of dispersing micronized TIo2, ZnO and other pigments
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols

Also Published As

Publication number Publication date
US5747639A (en) 1998-05-05
EP0906122A2 (de) 1999-04-07
EP0906122B1 (de) 2003-09-10
US5935564A (en) 1999-08-10
ES2206616T3 (es) 2004-05-16
WO1997032607A3 (en) 1997-11-13
DE69629949D1 (de) 2003-10-16
CA2248006C (en) 2002-05-28
DK0906122T3 (da) 2004-01-19
CA2248006A1 (en) 1997-09-12
JP2000506851A (ja) 2000-06-06
PT906122E (pt) 2003-12-31
DE69629949T2 (de) 2004-07-22
AU720399B2 (en) 2000-06-01
AU1410897A (en) 1997-09-22
WO1997032607A2 (en) 1997-09-12

Similar Documents

Publication Publication Date Title
ATE249244T1 (de) Aktivierte verbindungen und verfahren zur herstellung und reiningung
DE69508859D1 (de) Verfahren zur Reinigung von (-)-n-Isopulegol sowie gereinigtes (-)-n-Isopulegol enthaltende Zitrusparfümzusammensetzungen
ATE381963T1 (de) Verfahren zur herstellung von gereinigten partikeln
DE69106815D1 (de) Verfahren zur Herstellung von veränderten Kohlenstoffmolekularsieben zur Gastrennung.
ATE287948T1 (de) Plasmide dna reinigung durch peg-fällung und säulen-chromatographie
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
BR9916101A (pt) Purificação de compostos de ciclopeptìdeos equinocandinos
DE69504381D1 (de) Verfahren zur Reinigung von Wasserstoffgas
ATE214612T1 (de) Biologisch aktive substanzen, verfahren zur herstellung und sie enthaltende zusammensetzungen
DE69407272D1 (de) Verfahren zum reinigen von 20 cs)-camptothecin
DE59603541D1 (de) Verfahren zur Reinigung von Bisphenol-A
NZ308862A (en) Method for purifying thrombopoietin (tpo)
DE69502313D1 (de) Verfahren zur biologischen Reinigung von Gasströmen
DE59102062D1 (de) Verfahren zur biologischen Reinigung von Abluftströmen.
ATE210695T1 (de) Verfahren zur herstellung von poly(diorganosiloxanen), mischungen, enthaltend diese poly(diorganosiloxane) und deren verwendung
DE59200748D1 (de) Sorptionskolonne zur Abgasreinigung.
ATE509028T1 (de) Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
DE59603826D1 (de) Verfahren zur kontinuierlichen Herstellung von macrocyclischen Verbindungen
DE69303093D1 (de) Verfahren zur Reinigung von einem Hydrofluoralkan
ATE215968T1 (de) Verfahren zur reinigung von thrombomodulin
ATE173272T1 (de) Verfahren zur reaktivierung von gereinigten membranproteinen
DE69519203D1 (de) Verfahren zur Herstellung von Extrakten enthaltende polyphenalische oligomere Verbindungen von Catechin-Typ, aus pflanzenartigen Quellen, und diese erhaltene Extrakte
DE59003700D1 (de) Filterkörper und Verfahren zur Herstellung eines Filterkörpers.
DE69710628D1 (de) Verfahren zur Reinigung proteinhaltiger Abwässer
DE69416015D1 (de) Verfahren zur Herstellung von Substanzen zur Reinigung von Wasser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0906122

Country of ref document: EP

REN Ceased due to non-payment of the annual fee